Gsk (GSK) Free Cash Flow (2009 - 2026)
Gsk (GSK) posted quarterly Free Cash Flow of $440.1 million for Q2 2026, up 28.86% year-over-year from $341.5 million in Q2 2025, and down 79.22% quarter-over-quarter from $2.1 billion in Q1 2026.
Gsk (GSK) Free Cash Flow (2009 - 2026) Analysis & Trends
Gsk's Free Cash Flow history runs 18 years deep, the most recent figure standing at $440.1 million for Q2 2026.
- In Q2 2026, Free Cash Flow rose 28.86% year-over-year to $440.1 million; the TTM figure through Jun 2026 stood at $9.7 billion (up 21.77% YoY), while the FY2025 annual figure was $10.0 billion, up 21.23% from the prior year.
- Free Cash Flow for Q2 2026 stood at $440.1 million, down from $2.1 billion in the prior quarter.
- The five-year high for Free Cash Flow was $6.8 billion in Q4 2025, with the low at $341.5 million in Q2 2025.
- The 5-year median for Free Cash Flow is $1.9 billion (2022), against an average of $2.3 billion.
- Peak annual rise in Free Cash Flow reached 175.75% in 2024, while the deepest fall reached 87.54% in 2024.
- Gsk's Free Cash Flow stood at $5.3 billion in 2022, then retreated by 25.01% to $4.0 billion in 2023, then surged by 34.04% to $5.4 billion in 2024, then advanced by 26.15% to $6.8 billion in 2025, then plunged by 93.49% to $440.1 million in 2026.
- Business Quant data shows GSK's Free Cash Flow at $440.1 million in Q2 2026, $2.1 billion in Q1 2026, and $6.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.56 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 302.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 440.07 Mn |
| Jun 30, 2026 | 440.07 Mn |
| Mar 31, 2026 | 2.12 Bn |
| Mar 31, 2026 | 2.12 Bn |
| Dec 31, 2025 | 6.76 Bn |
| Dec 31, 2025 | 6.76 Bn |
| Sep 30, 2025 | 419.65 Mn |
| Sep 30, 2025 | 419.65 Mn |
| Jun 30, 2025 | 341.52 Mn |
| Jun 30, 2025 | 341.52 Mn |
| Mar 31, 2025 | 1.90 Bn |
| Mar 31, 2025 | 1.90 Bn |
| Dec 31, 2024 | 5.36 Bn |
| Dec 31, 2024 | 5.36 Bn |
| Sep 30, 2024 | 396.29 Mn |
| Sep 30, 2024 | 396.29 Mn |
| Jun 30, 2024 | 381.19 Mn |
| Jun 30, 2024 | 381.19 Mn |
| Mar 31, 2024 | 1.74 Bn |
| Mar 31, 2024 | 1.74 Bn |